1. Academic Validation
  2. CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia

CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia

  • J Med Chem. 2021 Feb 25;64(4):1835-1843. doi: 10.1021/acs.jmedchem.0c01489.
Joshua D Hansen 1 Matthew Correa 1 Matt Alexander 1 Mark Nagy 1 Dehua Huang 1 John Sapienza 1 Gang Lu 1 Laurie A LeBrun 1 Brian E Cathers 1 Weihong Zhang 2 Yang Tang 1 Massimo Ammirante 1 Rama K Narla 1 Joseph R Piccotti 1 Michael Pourdehnad 3 Antonia Lopez-Girona 1
Affiliations

Affiliations

  • 1 Bristol Myers Squibb, 10300 Campus Point Drive, Suite 100, San Diego, California 92121, United States.
  • 2 Bristol Myers Squibb, 556 Morris Avenue, Summit, New Jersey 07901, United States.
  • 3 Bristol Myers Squibb, 1500 Owens Street, Suite 600, San Francisco, California 94158, United States.
Abstract

Acute myeloid leukemia (AML) is marked by significant unmet clinical need due to both poor survival and high relapse rates where long-term disease control for most patients with relapsed or refractory AML remain dismal. Inspired to bring novel therapeutic options to these patients, we envisioned protein degradation as a potential therapeutic approach for the treatment of AML. Following this course, we discovered and pioneered a novel mechanism of action which culminated in the discovery of CC-90009. CC-90009 represents a novel protein degrader and the first Cereblon E3 Ligase modulating drug to enter clinical development that specifically targets GSPT1 (G1 to S phase transition 1) for proteasomal degradation. This manuscript briefly summarizes the mechanism of action, scientific rationale, medicinal chemistry, pharmacokinetic properties, and efficacy data for CC-90009, which is currently in phase 1 clinical development.

Figures
Products